AlphaCore Capital LLC Makes New Investment in Illumina, Inc. $ILMN

AlphaCore Capital LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,177 shares of the life sciences company’s stock, valued at approximately $208,000.

A number of other institutional investors have also recently made changes to their positions in the business. Corvex Management LP lifted its holdings in Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock worth $303,841,000 after buying an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 361.7% during the first quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock worth $165,484,000 after acquiring an additional 1,662,093 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of Illumina by 11,714.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after acquiring an additional 1,152,048 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Illumina by 51.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after purchasing an additional 667,978 shares during the period. Finally, PGGM Investments boosted its holdings in Illumina by 115.1% in the second quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company’s stock valued at $109,665,000 after purchasing an additional 614,973 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director directly owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 2.60% of the stock is currently owned by company insiders.

Illumina Stock Performance

Shares of ILMN opened at $129.64 on Wednesday. The company has a market capitalization of $19.81 billion, a price-to-earnings ratio of 16.41, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $153.06. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $106.28 and a 200 day moving average price of $98.39.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the company earned $1.14 earnings per share. The firm’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ILMN shares. Royal Bank Of Canada set a $124.00 price target on Illumina in a report on Tuesday, September 2nd. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th. Canaccord Genuity Group raised their target price on shares of Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a report on Friday, October 31st. TD Cowen lifted their price target on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Finally, UBS Group increased their price objective on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $115.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.